全文获取类型
收费全文 | 12346篇 |
免费 | 570篇 |
国内免费 | 103篇 |
专业分类
耳鼻咽喉 | 109篇 |
儿科学 | 227篇 |
妇产科学 | 85篇 |
基础医学 | 1409篇 |
口腔科学 | 331篇 |
临床医学 | 754篇 |
内科学 | 3586篇 |
皮肤病学 | 170篇 |
神经病学 | 693篇 |
特种医学 | 417篇 |
外科学 | 2291篇 |
综合类 | 31篇 |
一般理论 | 1篇 |
预防医学 | 236篇 |
眼科学 | 175篇 |
药学 | 823篇 |
中国医学 | 36篇 |
肿瘤学 | 1645篇 |
出版年
2023年 | 84篇 |
2022年 | 75篇 |
2021年 | 343篇 |
2020年 | 180篇 |
2019年 | 235篇 |
2018年 | 286篇 |
2017年 | 239篇 |
2016年 | 313篇 |
2015年 | 314篇 |
2014年 | 382篇 |
2013年 | 476篇 |
2012年 | 816篇 |
2011年 | 895篇 |
2010年 | 547篇 |
2009年 | 393篇 |
2008年 | 723篇 |
2007年 | 776篇 |
2006年 | 749篇 |
2005年 | 725篇 |
2004年 | 679篇 |
2003年 | 628篇 |
2002年 | 623篇 |
2001年 | 208篇 |
2000年 | 215篇 |
1999年 | 199篇 |
1998年 | 125篇 |
1997年 | 87篇 |
1996年 | 69篇 |
1995年 | 93篇 |
1994年 | 62篇 |
1993年 | 65篇 |
1992年 | 116篇 |
1991年 | 142篇 |
1990年 | 113篇 |
1989年 | 115篇 |
1988年 | 119篇 |
1987年 | 88篇 |
1986年 | 97篇 |
1985年 | 99篇 |
1984年 | 58篇 |
1983年 | 58篇 |
1982年 | 37篇 |
1981年 | 32篇 |
1980年 | 32篇 |
1979年 | 49篇 |
1978年 | 28篇 |
1977年 | 29篇 |
1973年 | 22篇 |
1970年 | 21篇 |
1969年 | 29篇 |
排序方式: 共有10000条查询结果,搜索用时 16 毫秒
1.
Kazuko Sakai Takayuki Takahama Mototsugu Shimokawa Koichi Azuma Masayuki Takeda Terufumi Kato Haruko Daga Isamu Okamoto Hiroaki Akamatsu Shunsuke Teraoka Akira Ono Tatsuo Ohira Toshihide Yokoyama Nobuyuki Yamamoto Kazuhiko Nakagawa Kazuto Nishio 《Molecular oncology》2021,15(1):126
The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third‐generation EGFR‐TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR‐TKI‐sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing—and T790M—EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation‐positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression‐free survival were observed between the sensitizing EGFR MF‐high and sensitizing EGFR MF‐low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
Abbreviations
- CIs
- confidence intervals
- ctDNA
- circulating tumor DNA
- ddPCR
- droplet digital PCR
- EGFR
- epidermal growth factor receptor
- MFs
- mutant fractions
- NGS
- next‐generation sequencing
- NSCLC
- non‐small cell lung cancer
- ORR
- overall response rate
- OS
- overall survival
- PD
- progressive disease
- PFS
- progression‐free survival
- PR
- partial response
- SD
- stable disease
- TKI
- tyrosine kinase inhibitor
2.
Hitoshi Kohsaka Tsuneyo Mimori Takashi Kanda Jun Shimizu Yoshihide Sunada Manabu Fujimoto Yasushi Kawaguchi Masatoshi Jinnin Yoshinao Muro Shoichiro Ishihara Hiroyuki Tomimitsu Akiko Ohta Takayuki Sumida 《The Journal of dermatology》2019,46(1):e1-e18
Although rheumatologists, neurologists and dermatologists see patients with polymyositis (PM) and dermatomyositis (DM), their management appears to vary depending on the physician's specialty. The aim of the present study was to establish the treatment consensus among specialists of the three fields to standardize the patient care. We formed a research team supported by a grant from the Ministry of Health, Labor and Welfare, Japan. Clinical questions (CQ) on the management of PM and DM were raised. A published work search on CQ was performed primarily using PubMed. Using the nominal group technique, qualified studies and results in the published work were evaluated and discussed to reach consensus recommendations. They were sent out to the Japan College of Rheumatology, Japanese Society of Neurology and Japanese Dermatological Association for their approval. We reached a consensus in 23 CQ and made recommendations and a decision tree for management was proposed. They were officially approved by the three scientific societies. In conclusion, a multidisciplinary treatment consensus for the management of PM and DM was established for the first time. 相似文献
3.
4.
5.
6.
Yamaoka Mai Yoshida Mahoko Nakashima Ayumu Doi Shigehiro Naito Takayuki Masaki Takao 《Clinical and experimental nephrology》2022,26(11):1111-1118
Clinical and Experimental Nephrology - The association between N-terminal pro-brain natriuretic peptide (NT-proBNP) and stroke in Japanese hemodialysis (HD) outpatients is unclear. Therefore, in... 相似文献
7.
Naohiro Sekiguchi Shinya Rai Wataru Munakata Kenshi Suzuki Hiroshi Handa Hirohiko Shibayama Tomoyuki Endo Yasuhito Terui Noriko Iwaki Noriko Fukuhara Hiro Tatetsu Shinsuke Iida Takayuki Ishikawa Ryota Shiibashi Koji Izutsu 《Cancer science》2020,111(9):3327-3337
Tirabrutinib is a second‐generation Bruton’s tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment‐naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström’s macroglobulinemia (WM). Patients were treated with tirabrutinib 480 mg once daily. The primary endpoint was major response rate (MRR; ≥ partial response). Secondary endpoints included overall response rate (ORR; ≥ minor response), time to major response (TTMR), progression‐free survival (PFS), overall survival (OS), and safety. In total, 27 patients (18 in Cohort A; 9 in Cohort B) were enrolled. The median age was 71 y, and the median serum immunoglobulin M level was 3600 mg/dL. Among the patients, 96.2% had the MYD88L265P mutation. MRR and ORR were 88.9% and 96.3%, respectively (Cohort A: MRR, 88.9%; ORR, 94.4%; Cohort B: MRR, 88.9%; ORR, 100%). Median TTMR was 1.87 mo. PFS and OS were not reached with a median follow‐up of 6.5 and 8.3 mo for Cohorts A and B, respectively. The most common adverse events (AEs) were rash (44.4%), neutropenia (25.9%), and leukopenia (22.2%), with most AEs classified as grade 1 or 2. Grade ≥ 3 AEs included neutropenia (11.1%), lymphopenia (11.1%), and leukopenia (7.4%). No grade 5 AEs were noted. All bleeding events were grade 1; none were associated with drug‐related atrial fibrillation or hypertension. Although the follow‐up duration was relatively short, the study met the primary endpoint. Therefore, tirabrutinib monotherapy is considered to be highly effective for both untreated and relapsed/refractory WM with a manageable safety profile. (JapicCTI‐173646). 相似文献
8.
9.
10.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217